Lack of nigrostriatal pathology in a rat model of proteasome inhibition

Annals of Neurology

Volumn 60, Issue 2, 2006, Pages 256-260

  Manning Boǧ, Amy B ^a   Reaney, Stephen H ^a   Chou, Vivian P ^a   Johnston, Louisa C ^a   McCormack, Alison L ^a   Johnston, Jennifer ^b   Langston, J William ^a   Di Monte, Donato A ^a  

^a PARKINSON S INSTITUTE   (United States)

^b ELAN PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEASOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; ENZYME INHIBITION; HISTOPATHOLOGY; LOCOMOTION; MALE; NERVE DEGENERATION; NEUROPATHOLOGY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SOLUBILIZATION;

ANIMALS; BIOLOGICAL MARKERS; CELL COUNT; CYSTEINE PROTEINASE INHIBITORS; DIMETHYL SULFOXIDE; ETHANOL; MALE; NEOSTRIATUM; OLIGOPEPTIDES; RATS; RATS, WISTAR; SOLVENTS; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 33746791044     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20938     Document Type: Article

References (18)

1. McNaught KS, Perl DP, Brownell AL, Olanow CW. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 2004;56:149-162.
2. Traenckner EB, Wilk S, Baeuerle PA. A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B. EMBO J 1994;13:5433-5441.
3. Tillerson JL, Caudle WM, Reveron ME, Miller GW. Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson's disease. Neuroscience 2003;119:899-911.
4. Kilpatrick IC, Jones MW, Phillipson OT. A semiautomated analysis method for catecholamines, indoleamines, and some prominent metabolites in microdissected regions of the nervous system: an isocratic HPLC technique employing coulometric detection and minimal sample preparation. J Neurochem 1986; 46:1865-1876.
5. McCormack AL, Thiruchelvam M, Manning-Bog AB, et al. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 2002;10:119-127.
6. Decker MJ, Hue GE, Caudle WM, et al. Episodic neonatal hypoxia evokes executive dysfunction and regionally specific alterations in markers of dopamine signaling. Neuroscience 2003; 117:417-425.
7. Manning-Boǧ AB, McCormack AL, Purisai MG, et al. Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J Neurosci 2003;23:3095-3099.
8. Manning-Boǧ AB, McCormack AL, Li J, et al. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice. J Biol Chem 2002;277:1641-1644.
9. McNaught K, Olanow CW. The proteasome inhibitor-induced model of Parkinson's disease. Ann Neurol 2006;60:243-247.
10. Zeng BY, Bukhatwa S, Hikima A, et al. Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats. Ann Neurol 2006;60:248-252.
11. Schapira AHV, Cleeter MWJ, Muddle JR, et al. Proteosomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Ann Neurol 2006;60:253-255.
12. Bové J, Zhou C, Jackson-Lewis V, et al. Proteasome inhibition and Parkinson's disease modeling. Ann Neurol 2006;60:260-264.
13. Kordower JH, Kanaan NM, Chu Y, et al. Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann Neurol 2006;60:264-268.
14. Lang AE, Beal MF. The proteosomal inhibition model of Parkinson's disease: "boon or bust"? Ann Neurol 2006;60: 158-161.
15. Eriksen JL, Wszolek Z, Petrucelli L. Molecular pathogenesis of Parkinson disease. Arch Neurol 2005;62:353-357.
16. Betarbet R, Sherer TB, Greenamyre JT. Ubiquitin-proteasome system and Parkinson's diseases. Exp Neurol 2005;191(suppl 1):S17-S27.
17. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605-608.
18. Spillantini MG, Crowther RA, Jakes R, et al. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett 1998;251:205-208.